Lansoprazole
- Generic Name
- Lansoprazole
- Brand Names
- Prevacid, Prevpac
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N3O2S
- CAS Number
- 103577-45-3
- Unique Ingredient Identifier
- 0K5C5T2QPG
- Background
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other patholog...
- Indication
Lansoprazole is used to reduce gastric acid secretion and is approved for short term treatment of active gastric ulcers, active duodenal ulcers, erosive reflux oesophagitis, symptomatic gastroesophageal reflux disease, and non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers. It may be used in the maintenance and healing of sever...
- Associated Conditions
- Duodenal Ulcer, Erosive Esophagitis, Helicobacter Pylori Infection, Symptomatic Gastroesophageal Reflux Disease (sGERD), Ulcer Healing, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Maintenance of healing Erosive esophagitis
- Associated Therapies
- -
Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 416
- Registration Number
- NCT06284876
- Locations
- 🇰🇷
Chung Ang University Hospital, Seoul, Korea, Republic of
Efficacy of Fexuprazan for Prevention or Control of Gastritis Symptoms in Patients on Treatment With Systemic Steroids
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 70
- Registration Number
- NCT05946135
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Miguel O'Ryan Gallardo
- Target Recruit Count
- 500
- Registration Number
- NCT05926804
- Locations
- 🇨🇱
Universidad de Chile, Santiago, Chile
🇨🇱Universidad de Aysén, Coyhaique, Chile
🇨🇱Universidad de la Frontera, Temuco, Chile
Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Finni Kollins
- Target Recruit Count
- 51
- Registration Number
- NCT05861687
- Locations
- 🇮🇩
Universitas Sumatera Utara General Hospital, Medan, North Sumatera, Indonesia
🇮🇩Haji Adam Malik General Hospital, Medan, North Sumatera, Indonesia
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- RAAS Nutritionals, LLC
- Target Recruit Count
- 71
- Registration Number
- NCT05417997
- Locations
- 🇹🇷
Kayseri City Hospital, Kayseri, Kayseri Province, Turkey
A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole
- Conditions
- Interventions
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Cinclus Pharma AG
- Target Recruit Count
- 248
- Registration Number
- NCT05055128
- Locations
- 🇧🇬
DCC XIV Sofia, Sofia, Sofia-Grad, Bulgaria
🇧🇬Medical Centre Asklepii, Dupnitsa, Bulgaria
🇧🇬Medical Center Prolet EOOD, Ruse, Bulgaria
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of Oral Doses of H008
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- Jiangsu Carephar Pharmaceutical Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05050188
- Locations
- 🇺🇸
Syneos Health, Miami, Florida, United States
Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2023-12-18
- Target Recruit Count
- 298
- Registration Number
- NCT04965298
- Locations
- 🇬🇧
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, United Kingdom
The Possible Efficacy and Safety of Lansoprazole Co-administration With Neoadjuvant Chemotherapy in Women With Breast Cancer
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 66
- Registration Number
- NCT04874935
- Locations
- 🇪🇬
Faculty of Pharmacy, Tanta, Egypt
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Phathom Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT04729101
- Locations
- 🇺🇸
Celerion, 2420 W Baseline Rd,, Tempe, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.